ZA989461B - Methods and compositions for the treatment of autoimmune disease using heat shock proteins - Google Patents

Methods and compositions for the treatment of autoimmune disease using heat shock proteins

Info

Publication number
ZA989461B
ZA989461B ZA989461A ZA989461A ZA989461B ZA 989461 B ZA989461 B ZA 989461B ZA 989461 A ZA989461 A ZA 989461A ZA 989461 A ZA989461 A ZA 989461A ZA 989461 B ZA989461 B ZA 989461B
Authority
ZA
South Africa
Prior art keywords
compositions
treatment
methods
autoimmune disease
heat shock
Prior art date
Application number
ZA989461A
Other languages
English (en)
Inventor
Pramod K Srivastava
Rajiv Y Chandawarkar
Original Assignee
Univ Fordham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fordham filed Critical Univ Fordham
Publication of ZA989461B publication Critical patent/ZA989461B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA989461A 1997-10-16 1998-10-16 Methods and compositions for the treatment of autoimmune disease using heat shock proteins ZA989461B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/951,789 US6007821A (en) 1997-10-16 1997-10-16 Method and compositions for the treatment of autoimmune disease using heat shock proteins

Publications (1)

Publication Number Publication Date
ZA989461B true ZA989461B (en) 1999-04-21

Family

ID=25492154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989461A ZA989461B (en) 1997-10-16 1998-10-16 Methods and compositions for the treatment of autoimmune disease using heat shock proteins

Country Status (7)

Country Link
US (1) US6007821A (de)
EP (1) EP1024701A4 (de)
JP (1) JP2002514570A (de)
AU (1) AU756472B2 (de)
CA (1) CA2306062A1 (de)
WO (1) WO1999018801A1 (de)
ZA (1) ZA989461B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6455493B1 (en) 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
WO1998012208A1 (en) 1996-09-20 1998-03-26 The University Of New Mexico Heat shock protein complexes
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
IT1290828B1 (it) * 1997-03-25 1998-12-11 Zetesis Spa Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
ATE231917T1 (de) * 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
US20060121051A1 (en) * 1998-02-19 2006-06-08 Kenten John H Heat shock fusion-based vaccine system
EP1829551B1 (de) * 1998-02-20 2010-09-29 University of Miami Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex
CN1367875A (zh) 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法
EP1076091A1 (de) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Arzneimittel für die Verhinderung und/oder Behandlung von Herzischämie, peripheren Gefässkrankheiten, Tumoren und Wunden
AU6636800A (en) * 1999-08-13 2001-03-13 Proteinix Company Heat shock fusion-based vaccine system
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20030108957A1 (en) * 2002-07-19 2003-06-12 The Wistar Institute Of Anatomy And Biology Biocidal molecules, macromolecular targets and methods of production and use
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US7179462B2 (en) * 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU2001266694C1 (en) * 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
CN100441223C (zh) 2000-06-26 2008-12-10 尼文塔生物制药公司 人乳头状瘤病毒治疗
US20040175360A1 (en) * 2000-06-29 2004-09-09 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
MXPA03003901A (es) 2000-11-01 2004-09-10 Univ California Peptidos inmuno-moduladores derivados de proteinas choque termico y sus usos.
BR0206995A (pt) 2001-02-05 2005-08-16 Stressgen Biotechnologies Corp Tratamento do vìrus da hepatite b
EP1381423A1 (de) * 2001-04-13 2004-01-21 Becton, Dickinson and Company Verfahren und vorrichtung zur intradermale abgabe von substanzen für systemischer absorption
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US20070129307A1 (en) * 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
WO2003001204A2 (en) * 2001-06-22 2003-01-03 The University Of British Columbia Type 1 diabetes diagnostics and therapeutics
BR0210628A (pt) 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
EP1551957A4 (de) * 2001-10-01 2007-01-24 Univ Duke Isoliertes polypeptid der grp94-ligandenbindungsdomäne und dafür codierende nukleinsäure, kristalline form davon sowie durchmusterungsverfahren, bei dem es verwendet wird
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
EP1572933A4 (de) * 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
ES2433915T3 (es) * 2002-05-21 2013-12-13 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
EP1539241A2 (de) * 2002-08-30 2005-06-15 Becton, Dickinson and Company Verfahren zur kontrolle der pharmakokinetik von immunomodulatorischen verbindungen
WO2004033657A2 (en) * 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
EP1578459A3 (de) * 2002-10-25 2005-11-23 University of Connecticut Health Center Gerät und verfahren für die immuntherapie von krebs durch kontrollierte zelllyse
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
JP2008500006A (ja) * 2003-05-21 2008-01-10 バイオテック トゥールス ソシエテ アノニム ペプチド複合体
BRPI0411428A (pt) * 2003-06-13 2006-07-25 Becton Dickinson Co distribuição intradérmica de agentes biologicamente ativos
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
AU2004291107B2 (en) 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
EP1765402A2 (de) * 2004-06-04 2007-03-28 Duke University Verfahren und zusammensetzungen zur verstärkung der immunität mittels in-vivo-abnahme von immunsuppressiver zellaktivität
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1846026A4 (de) * 2005-01-26 2008-07-02 Univ Johns Hopkins Antikrebs-dna-impfstoff mit plasmiden zur kodierung eines mutierten onkoprotein-antigens und von calreticulin
WO2007038083A2 (en) * 2005-09-21 2007-04-05 New York University Heat shock proteins from mycobacterium leprae and uses thereof
US7377231B2 (en) * 2005-10-19 2008-05-27 Ming-Liang Tsai Retractable pet house
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
JP2010532785A (ja) * 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． 炎症性疾患および自己免疫疾患の治療および予防
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
PT2484371E (pt) 2008-06-26 2015-03-03 Orphazyme Aps Uso da hsp70 como um regulador da atividade enzimática
US20110223196A1 (en) * 2008-11-21 2011-09-15 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
EP2673050B1 (de) * 2011-02-10 2016-03-30 Alfa Biogene International B.V. Hsp pflanzlichen ursprungs zur behandlung von nahrungsmittelallergie
US20140341935A1 (en) * 2011-08-30 2014-11-20 Loyola University Chicago MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE
ES2881860T3 (es) 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
JP6744318B2 (ja) 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
CN105749251A (zh) * 2016-04-08 2016-07-13 中国科学院微生物研究所 热休克蛋白gp96在预防和治疗1型糖尿病中的应用
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
RU2021117465A (ru) 2016-04-29 2021-07-22 Орфазим А/С Аримокломол для лечения ассоциированных с глюкоцереброзидазой нарушений
CN105963681B (zh) * 2016-05-09 2019-09-06 佛山热休生物技术有限公司 热休克蛋白gp96在治疗系统性红斑狼疮中的应用
CN106039287B (zh) * 2016-06-28 2019-12-31 中国科学院微生物研究所 热休克蛋白gp96在治疗类风湿性关节炎中的应用
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
JP2024538064A (ja) 2021-10-14 2024-10-18 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー ミクログリア活性化を抑制するための方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268170A (en) * 1986-09-09 1993-12-07 Yeda Research And Development Co., Ltd. Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
ATE127345T1 (de) * 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5578303A (en) * 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
NZ276672A (en) * 1993-11-30 1998-01-26 Univ Queensland Antagonists (abs) to chaperonin 10 (cpn 10) protein
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
DE69505376T2 (de) * 1994-06-09 1999-04-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Den Haag/S'gravenhage Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997024140A1 (en) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
EP0937258A2 (de) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Humane durch zellstress regulierte mhc class i gene
WO1998023735A1 (en) * 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Also Published As

Publication number Publication date
JP2002514570A (ja) 2002-05-21
WO1999018801A9 (en) 1999-07-01
US6007821A (en) 1999-12-28
AU756472B2 (en) 2003-01-16
EP1024701A1 (de) 2000-08-09
CA2306062A1 (en) 1999-04-22
AU1086299A (en) 1999-05-03
EP1024701A4 (de) 2000-12-06
WO1999018801A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
ZA967758B (en) Therapeutic and prophylactic methods using heat shock proteins
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
HUP9904239A3 (en) High level expression of proteins
IL132704A0 (en) Methods and compositions for the selective modification of nucleic acids
PL336420A1 (en) Improved methods of processing activated protein c
IL130396A0 (en) OB fusion protein compositions and methods
IL136454A0 (en) Compositions and methods for inducing gene expression
IL135338A0 (en) Methods and compositions for the selective modification of nucleic acids
ZA985704B (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
HUP0003206A3 (en) Methods of preparing and purifying 9-nitro-20-camptothecin
ZA200204635B (en) Fragments and antagonists of heat shock protein 60.
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP0998293A4 (de) Behandlungen von zytokin-bedingten krankheiten
IL129024A0 (en) Use of proteins as agent against autoimmune diseases
IL128570A0 (en) Protein kinases and uses thereof
ZA9710934B (en) Compositions and methods for administering pneumococal dna
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
HUP0000280A3 (en) Canine ob protein compositions and methods
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases
IL150113A0 (en) Fragments and antagonists of heat shock protein 60